Accepted for Publication: August 17, 2012.
Published Online: February 11, 2013. doi:10.1001/2013.jamaneurol.405
Author Contributions: Dr Marchant takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Marchant, Reed, Madison, Mack, Mungas, Chui, and Jagust. Acquisition of data: Reed, Sanossian, Kriger, Dhada, Mack, DeCarli, and Chui. Analysis and interpretation of data: Marchant, Reed, Madison, Kriger, DeCarli, Weiner, and Jagust. Drafting of the manuscript: Marchant. Critical revision of the manuscript for important intellectual content: Marchant, Reed, Sanossian, Madison, Kriger, Dhada, Mack, DeCarli, Weiner, Mungas, Chui, and Jagust. Statistical analysis: Marchant, Madison, Mack, and Mungas. Obtained funding: Reed, Weiner, Chui, and Jagust. Administrative, technical, and material support: Kriger, Dhada, DeCarli, Weiner, Chui, and Jagust. Study supervision: Jagust.
Conflict of Interest Disclosures: Dr Weiner reports (for 2010-2012) having served on scientific advisory boards for Eli Lilly & Company, Araclon and Institut Catala de Neurociencies Aplicades, the Research Advisory Committee on Gulf War Veterans' Illnesses, Biogen Idec, and Pfizer Inc; having served as a consultant for AstraZeneca, Araclon, Medivation/Pfizer Inc, Ipsen, TauRx Therapeutics Ltd, Bayer Healthcare, Biogen Idec, Exonhit Therapeutics SA, Servier, Synarc, Janssen, Harvard University, and KLJ Associates; having received travel funds from NeuroVigil, Inc, CHRU-Hopital Roger Salengro, Siemens, AstraZeneca, Geneva University Hospitals, Eli Lilly & Company, University of California, San Diego–Alzheimer's Disease Neuroimaging Initiative (ADNI), Paris University, Institut Catala de Neurociencies Aplicades, University of New Mexico School of Medicine, Ipsen, Clinical Trials on Alzheimer's Disease, Pfizer Inc, the AD/PD meeting (Conference on Alzheimer's and Parkinson's Diseases), Paul Sabatier University, Novartis, Tohoku University, Fundacio ACE, and Travel eDreams, Inc; having served on the editorial advisory boards of Alzheimer's & Dementia and Magnetic Resonance Imaging; having received honoraria from NeuroVigil, Inc, Institute Catala de Neurociencies Aplicades, PMDA (Pharmaceuticals and Medical Devices Agency)/Japanese Ministry of Health, Labour, and Welfare, Tohoku University, and Alzheimer's Drug Discovery Foundation; having received commercial entities research support from Merck and Avid; having received government entities research support from the Department of Defense and the Department of Veterans Affairs; and owning stock options in Synarc and Elan. Dr Weiner also reports that the following organizations contributed to the Foundation for the National Institutes of Health and thus to the National Institute on Aging–funded ADNI: Abbott, Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Anonymous Foundation, AstraZeneca, Bayer Healthcare, BioClinica, Inc (ADNI 2), Bristol-Myers Squibb, Cure Alzheimer's Fund, Eisai, Elan, Gene Network Sciences, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson & Johnson, Eli Lilly & Company, Medpace, Merck, Novartis, Pfizer Inc, Roche, Schering Plough, Synarc, and Wyeth.
Funding/Support: This work was supported by grants AG012435 (Drs Reed and Chui), AG031563 (Dr Reed), AG00266 (Dr Marchant), and AG10129 (Dr DeCarli) from the National Institutes of Health.
Online-Only Material: The video is available at .
Additional Contributions: Todd Bloom, MS, Shannon Buckley, BA, Adrian Herbert, MBA, and Ling Zheng, PhD, helped with data preparation, and Tadd Haight, PhD, Elizabeth Mormino, PhD, Gil Rabinovici, MD, Sylvia Villeneuve, PhD, and Miranka Wirth, PhD, provided helpful discussions throughout the project.